Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA Gene Overexpression
CAMBRIDGE, Mass.--(BUSINESS WIRE) April 09, 2024 -- Syros Pharmaceuticals (NASDAQ:SYRS), a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, today announced that the... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - April 9, 2024 Category: Pharmaceuticals Source Type: clinical trials
Practical Ultrasonographic Detection of Sarcopenia in Patients With Long-term Gastrectomy
Conditions: Sarcopenia; Gastrectomy Interventions: Diagnostic Test: USG, Grip strength, Chair stand test (CST) Sponsors: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC
Conditions: Renal Insufficiency; Upper Urinary Tract Urothelial Carcinoma; Solitary Kidney Interventions: Drug: DV; Drug: Toripalimab; Procedure: Laser surgery Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Conditions: Hepatocellular Carcinoma Interventions: Drug: Alectinib (Alecensa), Nivolumab (Opdivo) Sponsors: China Medical University Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Hepatocellular Carcinoma Liver Organoids
Conditions: Hepatocellular Carcinoma Interventions: Procedure: Liver biopsy Sponsors: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
PPIO-008S-1 Combined With Tislelizumab in Patients With Primary Residual Node-negative Esophageal Squamous Cell Carcinoma (ESCC) After Radical Resection With Neoadjuvant Immunotherapy Combined With Chemotherapy, PHASE II STUDY
Conditions: Postoperative Assistance for Esophageal Squamous Cell Carcinoma With Negative Lymph Nodes Interventions: Drug: Tegafur Sponsors: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Conditions: Neoadjuvant Therapy; Esophageal Squamous Cell Carcinoma Interventions: Drug: anlotinib; Radiation: Thoracic radiotherapy Sponsors: Army Medical Center of PLA Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer
Conditions: Prostate Cancer; Adaptive Radiotherapy; Quality of Life Sponsors: Jena University Hospital; University Hospital Schleswig-Holstein; Klinikum Stuttgart Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China
Conditions: Breast Neoplasm Female; Financial Toxicity; Financial Navigation Interventions: Behavioral: Financial Navigation; Other: Usual Care Sponsors: Fudan University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
Conditions: Urologic Neoplasms; Urogenital Neoplasms; Male Urogenital Diseases; Penile Cancer; Penile Squamous Cell Carcinoma; Locally Advanced Penile Carcinoma Interventions: Drug: Carboplatin/Paclitaxel; Drug: Pembrolizumab; Procedure: Partial or total penectomy with inguinal and/or pelvic lymph node dissection Sponsors: The Netherlands Cancer Institute; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Prehab for Lung and Esophageal Cancer
Conditions: Neoplasm of Lung; Neoplasms; Exercise; Surgery Interventions: Behavioral: Prehabilitation Sponsors: Nova Scotia Health Authority; Dalhousie University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Transhiatal Tunnel Valvuloplasty for Reconstruction Following the Laparoscopic Proximal Gastrectomy
Conditions: Proximal Gastrectomy; Gastric Tube; Valvulopathy Interventions: Procedure: the Transhiatal Tunnel Valvuloplasty technique Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer
Conditions: Triple-negative Breast Cancer Interventions: Drug: Quercetin; Drug: Dasatinib; Drug: Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
Conditions: Triple Negative Breast Cancer Interventions: Drug: Pembrolizumab; Drug: INBRX-106 Sponsors: Providence Health& Services; Inhibrx, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
Prospective Cohort Study of Immunotherapy Resistance in Metastatic Colorectal Cancer Patients With MSI
Conditions: Colorectal Cancer Metastatic; Microsatellite Instability-High Colorectal Cancer Sponsors: Federation Francophone de Cancerologie Digestive Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 9, 2024 Category: Research Source Type: clinical trials
